Sutro Biopharma Inc. (STRO) names Hans-Peter Gerber as Chief Scientific Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St set for higher open on Mideast deal hopes; healthcare in focus
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- Morgan Stanley Downgrades Circle Internet Group (CRCL) to Underweight
- Myanmar's detained former leader Aung San Suu Kyi meets Red Cross official
- Bernstein raises server shipment forecast as AI infrastructure spending grows
- Supernus and Indivior agree to all-stock merger of equals
- Curium to acquire Lantheus in deal valued at up to $8 billion
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
September 19, 2023 8:00 AM EDTSOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs, targeted oncology, and novel biotherapeutic platforms.
Dr. Gerbers deep experience in the development of ADCs and other novel therapeutics make him an invaluable addition to... More
